Related Experiment Video
Updated: Mar 16, 2026
09:39
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
10.2K
Resolving Pain: Preclinical Insights into the Analgesic Mechanisms of RvD1
Geovana Martelossi-Cebinelli1, Tiago H Zaninelli2, Rubia Casagrande3
1Laboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology, and General Pathology, Center of Biological Sciences, Londrina State University, Londrina 86057-970, PR, Brazil.
Current Reviews in Clinical and Experimental Pharmacology
|March 15, 2026
Summary
Resolvin D1 (RvD1), derived from omega-3 fatty acids, shows promise as a safer pain reliever by modulating immune, nerve, and glial responses during inflammation.
Area of Science:
- Biomedical Science
- Neuroscience
- Immunology
Background:
- Pain is a protective response exacerbated by inflammation via nociceptive neuron sensitization.
- Current pain medications (NSAIDs, glucocorticoids, opioids) have significant side effects, driving the search for safer alternatives.
- Specialized pro-resolving mediators (SPMs) from polyunsaturated fatty acids are being investigated for analgesic properties.
Purpose of the Study:
- To explore the analgesic mechanisms of Resolvin D1 (RvD1) in preclinical pain models.
- To highlight RvD1's potential as a therapeutic agent for inflammatory pain.
Main Methods:
- Preclinical models were used to investigate RvD1's effects on pain and inflammation.
- Analysis focused on RvD1's role in modulating immunological, neuronal, and glial responses.
Main Results:
- Resolvin D1 (RvD1) demonstrates multimodal action in managing pain and inflammation.
- RvD1 effectively regulates key immunological, neuronal, and glial pathways involved in pain.
Conclusions:
- RvD1 is a promising molecule for resolving inflammatory and painful conditions.
- Further research into RvD1's mechanisms could lead to novel pain therapeutics.
Keywords:
Resolvin D1Resolvinsinflammationpainresolution of inflammation.specialized pro-resolving mediatorsMore Related Videos
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
01:23Local Anesthetics: Mechanism of Action
3.9K
Local anesthetics (LAs) block sensory and motor impulses by inhibiting the sodium channels on the nerve cell membranes. This induces temporary loss of sensation, relieving pain in a specific body area.
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
3.9K
01:25Analgesia and Pain Management
2.7K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.7K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
01:23Antihypertensive Drugs: Vasodilators
2.4K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
01:22Opioid Receptors: Overview
6.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.0K